

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Jordan Julie</u> (Last) (First) (Middle) <u>C/O HOMOLOGY MEDICINES, INC.</u> <u>ONE PATRIOTS PARK</u> (Street) <u>BEDFORD MA 01730</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/07/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>Homology Medicines, Inc. [FIXX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> Officer (give title below) <u>Chief Medical Officer</u> 10% Owner Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>2,519</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Employee Stock Option (Right to Buy)</u>	<u>(1)</u>	<u>06/02/2031</u>	<u>Common Stock</u>	<u>65,000</u>	<u>6.53</u>	<u>D</u>	
<u>Employee Stock Option (Right to Buy)</u>	<u>(2)</u>	<u>02/24/2032</u>	<u>Common Stock</u>	<u>56,000</u>	<u>2.71</u>	<u>D</u>	
<u>Employee Stock Option (Right to Buy)</u>	<u>(3)</u>	<u>03/02/2032</u>	<u>Common Stock</u>	<u>9,000</u>	<u>3.59</u>	<u>D</u>	
<u>Employee Stock Option (Right to Buy)</u>	<u>(4)</u>	<u>02/23/2033</u>	<u>Common Stock</u>	<u>143,000</u>	<u>1.6</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(5)</u>	<u>(6)</u>	<u>Common Stock</u>	<u>350</u>	<u>(6)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(7)</u>	<u>(6)</u>	<u>Common Stock</u>	<u>5,360</u>	<u>(6)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(8)</u>	<u>(6)</u>	<u>Common Stock</u>	<u>1,340</u>	<u>(6)</u>	<u>D</u>	
<u>Restricted Stock Units</u>	<u>(9)</u>	<u>(6)</u>	<u>Common Stock</u>	<u>24,000</u>	<u>(6)</u>	<u>D</u>	

Explanation of Responses:

1. The option vests or has vested as to 25% of the underlying shares on May 3, 2022 and in 36 substantially equal monthly installments upon the Reporting Person's completion of each full month of service thereafter so that such option will become fully vested on May 3, 2025.

2. The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.

3. The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.

4. The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023 so that such option will become fully vested on January 1, 2027.

5. The restricted stock units will vest and settle in full on August 2, 2023.

6. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.

7. The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.

8. The restricted stock units will vest and settle as to one half of the restricted stock units on each of January 1, 2024 and January 1, 2025.

9. The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.

Remarks:

Exhibit 24 - Power of Attorney.

/s/ Paul Alloway,
Attorney-in-Fact for Julie 03/16/2023
Jordan

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Homology Medicines, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-facts discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is any Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of March, 2023.

By: /s/ Julie Jordan

Name: Julie Jordan

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

1. W. Bradford Smith

2. Paul Alloway
3. Albert Seymour